Dapeng Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dapeng Sun has a total of 373 co-authors. Here are the top co-authors by number of shared publications:
- Zhongrong Miao
Capital Medical University
33 shared publications - Xiaochuan Huo
Department of Cerebral Vascular Disease, Neurological Disease Center, Beijing Anzhen Hospital, Capital Medical University, China (X.Z., X.T., S.L., X.H.).
24 shared publications - Ning Ma
Department of Interventional Neuroradiology, Beijing Tiantan Hospital Capital Medical University Beijing China
19 shared publications - Dapeng Mo
Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
18 shared publications - Thanh N. Nguyen
Boston Medical Center
16 shared publications - Yuesong Pan
Capital Medical University
14 shared publications
Latest Publications
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Sex‐Stratified Outcomes in Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis: The BASIS Subgroup Analysis
Background: The BASIS (Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis) trial demonstrated that balloon angioplasty plus aggressive medical management was superior to aggressive medical management alone for symptomatic intracranial atherosclerotic stenosis. However, whether sex modifies this treatment effect is unknown. Methods: This prespecified secondary analysis of the BASIS randomized controlled trial included 501 patients with symptomatic intracranial atherosclerotic stenosis from 31 Chinese centers (November 2018 to April 2022). Baseline characteristics and outcomes were compared between sexes and across treatment arms within each sex. The primary outcome was stroke or death within 30 days, or ischemic stroke in the qualifying artery territory or revascularization beyond 30 days through 12 months. Results: Among 501 patients (mean age, 58 years), 158 (31.5%) were women. No significant sex‐by‐treatment interaction was observed for primary or key secondary outcomes (all P for interaction >0.05). In sex‐stratified analyses, balloon angioplasty reduced primary outcome risk versus aggressive medical management in men (2.9% versus 11.1%; hazard ratio [HR]=0.21 [95% CI, 0.07–0.65]; P =0.01). In women, the effect favored balloon angioplasty but was not statistically significant (7.8% versus 18.5%; HR=0.37 [95% CI, 0.14–1.01]; P =0.051). Conclusions: No significant interaction between sex and treatment effect was found, suggesting balloon angioplasty's benefit relative to aggressive medical management does not clearly differ by sex. Sex‐stratified results showed significant benefit in men and a nonsignificant trend in women, but the study lacked power for definitive interaction testing, so findings are exploratory. Further research is needed to confirm these findings in broader populations. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03703635.
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Sex‐Stratified Outcomes in Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis: The BASIS Subgroup Analysis
Background: The BASIS (Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis) trial demonstrated that balloon angioplasty plus aggressive medical management was superior to aggressive medical management alone for symptomatic intracranial atherosclerotic stenosis. However, whether sex modifies this treatment effect is unknown. Methods: This prespecified secondary analysis of the BASIS randomized controlled trial included 501 patients with symptomatic intracranial atherosclerotic stenosis from 31 Chinese centers (November 2018 to April 2022). Baseline characteristics and outcomes were compared between sexes and across treatment arms within each sex. The primary outcome was stroke or death within 30 days, or ischemic stroke in the qualifying artery territory or revascularization beyond 30 days through 12 months. Results: Among 501 patients (mean age, 58 years), 158 (31.5%) were women. No significant sex‐by‐treatment interaction was observed for primary or key secondary outcomes (all P for interaction >0.05). In sex‐stratified analyses, balloon angioplasty reduced primary outcome risk versus aggressive medical management in men (2.9% versus 11.1%; hazard ratio [HR]=0.21 [95% CI, 0.07–0.65]; P =0.01). In women, the effect favored balloon angioplasty but was not statistically significant (7.8% versus 18.5%; HR=0.37 [95% CI, 0.14–1.01]; P =0.051). Conclusions: No significant interaction between sex and treatment effect was found, suggesting balloon angioplasty's benefit relative to aggressive medical management does not clearly differ by sex. Sex‐stratified results showed significant benefit in men and a nonsignificant trend in women, but the study lacked power for definitive interaction testing, so findings are exploratory. Further research is needed to confirm these findings in broader populations. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03703635.
- 29 October 2026
- Published by Wolters Kluwer Health in Stroke
Relationship Between the eTICI Score Before Randomization and 90-Day Outcome: A Post Hoc Analysis of ANGEL-TNK Trial
BACKGROUND: Successful thrombectomy recanalization combined with intraarterial thrombolysis showed potential benefits in achieving excellent outcomes in recent trials, but the results were inconsistent. We performed this study to investigate the efficacy and safety of interarterial thrombolysis in patients stratified by expanded Thrombolysis in Cerebral Infarction (eTICI) score after thrombectomy. METHODS: This is a prespecified secondary analysis of the ANGEL-TNK trial (Intraarterial Recombinant Human TNK-tPA Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization; multicenter, randomized, open-label, blinded end point). Participants who had anterior circulation large artery occlusion were enrolled and randomized (1:1) to interarterial tenecteplase (TNK; 0.125 mg/kg) or standard medical management after eTICI 2b50 to 3 reperfusion. The primary outcome was the rate of 90-day modified Rankin Scale score 0 to 1. Safety outcomes included symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours, and death within 90 days. RESULTS: Of the 253 patients enrolled, 164 were in the eTICI 2b50 to 67 group, and 89 were in the eTICI 2c to 3 group. Interarterial TNK after EVT was associated with a higher rate of modified Rankin Scale score 0 to 1 at 90 days in patients with an eTICI score of 2b50 to 67 (39 [44.8%] versus 15 [19.5%]; relative risk, 2.08 [95% CI, 1.35–3.21]; P =0.001), but not in those with eTICI 2c to 3 (12 [30.8%] versus 19 [38.0%]; relative risk, 0.84 [95% CI, 0.29–2.44]; P =0.749). In the eTICI 2c to 3 group, interarterial TNK resulted in more cases of any intracranial hemorrhage within 48 hours (13 [33.3%] versus 10 [20.0%]; relative risk, 1.70 [95% CI, 1.05–2.77]; P =0.032), but not in the eTICI 2b50 to 67 group (18 [20.7%] versus 25 [32.5%]; relative risk, 0.65 [95% CI, 0.34–1.22]; P =0.176). The difference was not observed in symptomatic intracranial hemorrhage within 48 hours or death within 90 days in either group. CONCLUSIONS: Interarterial TNK after EVT provides additional benefits for excellent outcomes, defined as a modified Rankin Scale score of 0 to 1 at 90 days, in patients with an eTICI score of 2b50 to 67, but not in those with eTICI 2c to 3. It increases the risk of any intracranial hemorrhage in patients with an eTICI score of 2c to 3, without elevating the risk of symptomatic intracranial hemorrhage or death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05624190.
- 29 October 2026
- Published by Wolters Kluwer Health in Stroke
Relationship Between the eTICI Score Before Randomization and 90-Day Outcome: A Post Hoc Analysis of ANGEL-TNK Trial
BACKGROUND: Successful thrombectomy recanalization combined with intraarterial thrombolysis showed potential benefits in achieving excellent outcomes in recent trials, but the results were inconsistent. We performed this study to investigate the efficacy and safety of interarterial thrombolysis in patients stratified by expanded Thrombolysis in Cerebral Infarction (eTICI) score after thrombectomy. METHODS: This is a prespecified secondary analysis of the ANGEL-TNK trial (Intraarterial Recombinant Human TNK-tPA Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization; multicenter, randomized, open-label, blinded end point). Participants who had anterior circulation large artery occlusion were enrolled and randomized (1:1) to interarterial tenecteplase (TNK; 0.125 mg/kg) or standard medical management after eTICI 2b50 to 3 reperfusion. The primary outcome was the rate of 90-day modified Rankin Scale score 0 to 1. Safety outcomes included symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours, and death within 90 days. RESULTS: Of the 253 patients enrolled, 164 were in the eTICI 2b50 to 67 group, and 89 were in the eTICI 2c to 3 group. Interarterial TNK after EVT was associated with a higher rate of modified Rankin Scale score 0 to 1 at 90 days in patients with an eTICI score of 2b50 to 67 (39 [44.8%] versus 15 [19.5%]; relative risk, 2.08 [95% CI, 1.35–3.21]; P =0.001), but not in those with eTICI 2c to 3 (12 [30.8%] versus 19 [38.0%]; relative risk, 0.84 [95% CI, 0.29–2.44]; P =0.749). In the eTICI 2c to 3 group, interarterial TNK resulted in more cases of any intracranial hemorrhage within 48 hours (13 [33.3%] versus 10 [20.0%]; relative risk, 1.70 [95% CI, 1.05–2.77]; P =0.032), but not in the eTICI 2b50 to 67 group (18 [20.7%] versus 25 [32.5%]; relative risk, 0.65 [95% CI, 0.34–1.22]; P =0.176). The difference was not observed in symptomatic intracranial hemorrhage within 48 hours or death within 90 days in either group. CONCLUSIONS: Interarterial TNK after EVT provides additional benefits for excellent outcomes, defined as a modified Rankin Scale score of 0 to 1 at 90 days, in patients with an eTICI score of 2b50 to 67, but not in those with eTICI 2c to 3. It increases the risk of any intracranial hemorrhage in patients with an eTICI score of 2c to 3, without elevating the risk of symptomatic intracranial hemorrhage or death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05624190.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9)
Balloon Angioplasty by Prior Stroke History in Intracranial Artery Stenosis: A Post Hoc Analysis of the BASIS Trial
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9)
Balloon Angioplasty by Prior Stroke History in Intracranial Artery Stenosis: A Post Hoc Analysis of the BASIS Trial
- Open Access
- 26 June 2026
- Published by BMJ in Stroke and Vascular Neurology
Predictors of functional outcomes after endovascular therapy in acute large infarct: an ANGEL-ASPECT subanalysis
Background and purpose: Recent randomised clinical trials have shown that endovascular treatment (EVT) for patients with acute ischaemic stroke (AIS) and a large infarct core is safe and effective. This study sought to identify which factors predict favourable outcomes in AIS patients with a large infarct core who received EVT in the ANGEL-ASPECT trial. Methods: Patients from the ANGEL-ASPECT trial receiving EVT were enrolled in this analysis. They were categorised based on 90-day outcomes: good functional outcome (modified Rankin Scale (mRS) score 0–2) and independent ambulation (mRS score 0–3). A comparison of baseline and procedural characteristics was performed across the groups and logistic regression was performed to identify predictors of favourable outcomes. Results: Of 230 AIS participants with large infarct core undergoing EVT, independent predictors differed between outcome levels. For functional independence (mRS 0–2), predictors were male sex, lower systolic blood pressure (SBP) and National Institutes of Health Stroke Scale (NIHSS) score, smaller infarct volume, fewer thrombectomy attempts, and notably, the presence of early neurological improvement (ENI) at 36 hours (OR 19.62, 95% CI 2.28 to 168.52). For independent ambulation (mRS 0–3), predictors were younger age, lower SBP and NIHSS score, successful reperfusion, lower platelet-to-lymphocyte ratio and absence of decompressive hemicraniectomy (OR 20.00, 95% CI 2.04 to 196.08). Conclusions: This analysis delineates distinct predictors for different levels of recovery after EVT in large-core stroke. Beyond confirming the prognostic value of established factors (such as age, NIHSS and reperfusion), it highlights the novel high-impact prognostic factors for large-core AIS patients post-EVT: ENI for functional independence. Furthermore, the need for decompressive hemicraniectomy, a marker of severe cerebral oedema, was strongly linked to a lower probability of achieving independent ambulation. These findings may aid in early prognostication and refined patient management for this high-risk population. Trial registration number: NCT04551664 .
- 26 June 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessPredictors of functional outcomes after endovascular therapy in acute large infarct: an ANGEL-ASPECT subanalysis
Background and purpose: Recent randomised clinical trials have shown that endovascular treatment (EVT) for patients with acute ischaemic stroke (AIS) and a large infarct core is safe and effective. This study sought to identify which factors predict favourable outcomes in AIS patients with a large infarct core who received EVT in the ANGEL-ASPECT trial. Methods: Patients from the ANGEL-ASPECT trial receiving EVT were enrolled in this analysis. They were categorised based on 90-day outcomes: good functional outcome (modified Rankin Scale (mRS) score 0–2) and independent ambulation (mRS score 0–3). A comparison of baseline and procedural characteristics was performed across the groups and logistic regression was performed to identify predictors of favourable outcomes. Results: Of 230 AIS participants with large infarct core undergoing EVT, independent predictors differed between outcome levels. For functional independence (mRS 0–2), predictors were male sex, lower systolic blood pressure (SBP) and National Institutes of Health Stroke Scale (NIHSS) score, smaller infarct volume, fewer thrombectomy attempts, and notably, the presence of early neurological improvement (ENI) at 36 hours (OR 19.62, 95% CI 2.28 to 168.52). For independent ambulation (mRS 0–3), predictors were younger age, lower SBP and NIHSS score, successful reperfusion, lower platelet-to-lymphocyte ratio and absence of decompressive hemicraniectomy (OR 20.00, 95% CI 2.04 to 196.08). Conclusions: This analysis delineates distinct predictors for different levels of recovery after EVT in large-core stroke. Beyond confirming the prognostic value of established factors (such as age, NIHSS and reperfusion), it highlights the novel high-impact prognostic factors for large-core AIS patients post-EVT: ENI for functional independence. Furthermore, the need for decompressive hemicraniectomy, a marker of severe cerebral oedema, was strongly linked to a lower probability of achieving independent ambulation. These findings may aid in early prognostication and refined patient management for this high-risk population. Trial registration number: NCT04551664 .
- 9 April 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Endovascular treatment for extracranial internal carotid artery occlusions with large infarcts: ANGEL-ASPECT subanalysis
Background and purpose Endovascular treatment (EVT) is superior to medical management (MM) for patients with acute large infarcts. However, evidence remains limited for patients with large infarcts with extracranial internal carotid artery occlusion (e-ICAO) . This study compares EVT and MM in patients with large infarcts due to e-ICAO. Methods Patients with e-ICAO were selected from the ANGEL-ASPECT randomized controlled trial conducted at 46 stroke centers across China between October 2, 2020 and May 18, 2022. The efficacy and safety of EVT and MM were compared in these patients. The primary outcome was the 90-day modified Rankin Scale (mRS) score, and secondary outcomes were 90-day/1-year functional independence and independent ambulation and 1-year mRS score. Safety endpoints were symptomatic intracranial hemorrhage (sICH) and 90-day mortality. Results Of 456 enrolled patients, 76 (16.7%) had e-ICAO (41 EVT, 35 MM). 90-day mRS distribution (4 (2–6) vs 4 (3–5), adjusted common OR (acOR) 1.27 (95% CI 0.54 to 2.98); P=0.579), 90-day independent ambulation (46.3% vs 31.4%, aRR 1.29 (95% CI 0.70 to 2.38); P=0.415), 90-day functional independence (29.3% vs 5.7%, aRR 3.74 (95% CI 0.89 to 15.61); P=0.071), 1-year mRS score (4 (2–6) vs 4 (3–5), acOR 0.86 (95% CI 0.35 to 2.10), P=0.735), 1-year independent ambulation (48.7% vs 46.9%, aRR 0.79 (95% CI 0.48 to 1.31); P=0.367), and 1-year functional independence (30.8% vs 15.6%, aRR 1.76 (95% CI 0.67 to 4.65); P=0.252) were not significantly different between the EVT and MM groups. sICH was higher in the EVT group than in the MM group (2.4% vs 0, P=0.356) and 90-day mortality (19.5% vs.8.6%, aHR 2.17 (95%CI 0.59 to 8.03); P=0.247) was similar between the two groups. Conclusions In patients with large infarcts and e-ICAO, EVT did not improve clinical outcomes at either 90 days or 1 year compared with MM without increasing the risk of sICH and mortality. Trial registration number NCT04551664.
- 9 April 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Endovascular treatment for extracranial internal carotid artery occlusions with large infarcts: ANGEL-ASPECT subanalysis
Background and purpose Endovascular treatment (EVT) is superior to medical management (MM) for patients with acute large infarcts. However, evidence remains limited for patients with large infarcts with extracranial internal carotid artery occlusion (e-ICAO) . This study compares EVT and MM in patients with large infarcts due to e-ICAO. Methods Patients with e-ICAO were selected from the ANGEL-ASPECT randomized controlled trial conducted at 46 stroke centers across China between October 2, 2020 and May 18, 2022. The efficacy and safety of EVT and MM were compared in these patients. The primary outcome was the 90-day modified Rankin Scale (mRS) score, and secondary outcomes were 90-day/1-year functional independence and independent ambulation and 1-year mRS score. Safety endpoints were symptomatic intracranial hemorrhage (sICH) and 90-day mortality. Results Of 456 enrolled patients, 76 (16.7%) had e-ICAO (41 EVT, 35 MM). 90-day mRS distribution (4 (2–6) vs 4 (3–5), adjusted common OR (acOR) 1.27 (95% CI 0.54 to 2.98); P=0.579), 90-day independent ambulation (46.3% vs 31.4%, aRR 1.29 (95% CI 0.70 to 2.38); P=0.415), 90-day functional independence (29.3% vs 5.7%, aRR 3.74 (95% CI 0.89 to 15.61); P=0.071), 1-year mRS score (4 (2–6) vs 4 (3–5), acOR 0.86 (95% CI 0.35 to 2.10), P=0.735), 1-year independent ambulation (48.7% vs 46.9%, aRR 0.79 (95% CI 0.48 to 1.31); P=0.367), and 1-year functional independence (30.8% vs 15.6%, aRR 1.76 (95% CI 0.67 to 4.65); P=0.252) were not significantly different between the EVT and MM groups. sICH was higher in the EVT group than in the MM group (2.4% vs 0, P=0.356) and 90-day mortality (19.5% vs.8.6%, aHR 2.17 (95%CI 0.59 to 8.03); P=0.247) was similar between the two groups. Conclusions In patients with large infarcts and e-ICAO, EVT did not improve clinical outcomes at either 90 days or 1 year compared with MM without increasing the risk of sICH and mortality. Trial registration number NCT04551664.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 641-649
Time-Dependent Impact of Mismatch Profiles on Outcomes Following Endovascular Thrombectomy for Large Ischemic Stroke
BACKGROUND: Endovascular therapy (EVT) has demonstrated efficacy in patients with large core infarctions, yet favorable outcomes remain limited. Although mismatch profiles have long informed EVT decision-making in small-core strokes, their prognostic significance in large-core infarcts remains uncertain and may be affected by time from symptom onset. This study aims to evaluate the relationship between mismatch profiles, time distribution, and EVT efficacy in patients with large ischemic cores. METHODS: This was a secondary posthoc analysis of the ANGEL-ASPECT trial (Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core) in patients with large ischemic cores randomized to EVT or medical management. The primary outcome was the modified Rankin Scale score of 0 to 3 at 90 days. Analyses were stratified by mismatch profile (mismatch ratio ≥1.8 and volume ≥15 mL) and onset-to-imaging time (≤6 hours versus >6 hours). RESULTS: For the primary end point (modified Rankin Scale score, 0–3 at 90 days), no significant treatment-by-time interaction was observed ( P for interaction=0.412); within time strata, treatment-by-mismatch interaction tests were also nonsignificant (≤6 hours, P for interaction=0.166; >6 hours, P for interaction=0.301). In the early window (≤6 hours), EVT was associated with higher odds of favorable functional outcome (modified Rankin Scale score, 0–3 at 90 days) in patients with mismatch (48.9% versus 28.4%; odds ratio, 2.41 [95% CI, 1.28–4.55]; P =0.006), but not in those without mismatch (23.8% versus 27.3%; odds ratio, 0.83 [95% CI, 0.21–3.29]; P =0.795). In the late window (>6 hours), EVT was not associated with a significant improvement in modified Rankin Scale score 0 to 3 in either subgroup. CONCLUSIONS: Among patients with large infarct cores, the absence of mismatch was more common in the early time window and was associated with diminished benefit from EVT. These results suggest that mismatch evaluation—even in early presenting patients—may help inform treatment selection for patients with large ischemic cores. All interaction tests were nonsignificant; these findings are hypothesis‑generating and require prospective, prespecified confirmation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04551664.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 641-649
Time-Dependent Impact of Mismatch Profiles on Outcomes Following Endovascular Thrombectomy for Large Ischemic Stroke
BACKGROUND: Endovascular therapy (EVT) has demonstrated efficacy in patients with large core infarctions, yet favorable outcomes remain limited. Although mismatch profiles have long informed EVT decision-making in small-core strokes, their prognostic significance in large-core infarcts remains uncertain and may be affected by time from symptom onset. This study aims to evaluate the relationship between mismatch profiles, time distribution, and EVT efficacy in patients with large ischemic cores. METHODS: This was a secondary posthoc analysis of the ANGEL-ASPECT trial (Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core) in patients with large ischemic cores randomized to EVT or medical management. The primary outcome was the modified Rankin Scale score of 0 to 3 at 90 days. Analyses were stratified by mismatch profile (mismatch ratio ≥1.8 and volume ≥15 mL) and onset-to-imaging time (≤6 hours versus >6 hours). RESULTS: For the primary end point (modified Rankin Scale score, 0–3 at 90 days), no significant treatment-by-time interaction was observed ( P for interaction=0.412); within time strata, treatment-by-mismatch interaction tests were also nonsignificant (≤6 hours, P for interaction=0.166; >6 hours, P for interaction=0.301). In the early window (≤6 hours), EVT was associated with higher odds of favorable functional outcome (modified Rankin Scale score, 0–3 at 90 days) in patients with mismatch (48.9% versus 28.4%; odds ratio, 2.41 [95% CI, 1.28–4.55]; P =0.006), but not in those without mismatch (23.8% versus 27.3%; odds ratio, 0.83 [95% CI, 0.21–3.29]; P =0.795). In the late window (>6 hours), EVT was not associated with a significant improvement in modified Rankin Scale score 0 to 3 in either subgroup. CONCLUSIONS: Among patients with large infarct cores, the absence of mismatch was more common in the early time window and was associated with diminished benefit from EVT. These results suggest that mismatch evaluation—even in early presenting patients—may help inform treatment selection for patients with large ischemic cores. All interaction tests were nonsignificant; these findings are hypothesis‑generating and require prospective, prespecified confirmation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04551664.
- Open Access
- 21 January 2026
- Published by BMJ in Stroke and Vascular Neurology
Factors associated with infarct volume growth after mechanical thrombectomy in large core infarction: ANGEL-ASPECT insights
Background: Infarct volume growth (IVG) correlates with outcomes and may represent a prognostic imaging biomarker in acute ischaemic stroke due to anterior circulation large vessel occlusion (LVO). This study aims to identify factors associated with IVG after mechanical thrombectomy (MT) in patients with large core infarction. Methods: This is a post hoc analysis of the Endovascular Therapy in Anterior Circulation Large Vessel Occlusion with a Large Infarct randomised trial. IVG was calculated as final infarct volume minus baseline infarct volume (BIV). The optimal IVG threshold for predicting 90-day favourable outcomes (modified Rankin Scale score 0–3) was determined using receiver operating characteristic (ROC) curve analysis, maximising both sensitivity and specificity. Factors associated with IVG were identified using multivariate logistic regression analyses. Results: Among 228 included patients, ROC analysis identified an optimal IVG threshold of 105 mL for predicting favourable 90-day outcomes (area under the curve=0.71; specificity=0.85, sensitivity=0.53). Patients were stratified into mild (IVG <105 mL, n=150) and severe (IVG ≥105 mL, n=78) groups. Multivariate logistic regression identified BIV (OR 1.02, 95% CI 1.00 to 1.03; p<0.01), admission blood glucose (OR 1.20, 95% CI 1.04 to 1.37; p=0.01), time from puncture to recanalisation (OR 1.01, 95% CI 1.00 to 1.02; p=0.049) and recanalisation at 36 hours (±12 hours) (OR 0.19, 95% CI 0.05 to 0.72; p=0.01) as independent factors associated with IVG. Conclusion: IVG after MT significantly correlates with clinical outcomes. Identification of modifiable IVG determinants after MT may inform periprocedural management strategies in patients with large infarct due to LVO. Trial registration number: NCT04551664 .
- 21 January 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessFactors associated with infarct volume growth after mechanical thrombectomy in large core infarction: ANGEL-ASPECT insights
Background: Infarct volume growth (IVG) correlates with outcomes and may represent a prognostic imaging biomarker in acute ischaemic stroke due to anterior circulation large vessel occlusion (LVO). This study aims to identify factors associated with IVG after mechanical thrombectomy (MT) in patients with large core infarction. Methods: This is a post hoc analysis of the Endovascular Therapy in Anterior Circulation Large Vessel Occlusion with a Large Infarct randomised trial. IVG was calculated as final infarct volume minus baseline infarct volume (BIV). The optimal IVG threshold for predicting 90-day favourable outcomes (modified Rankin Scale score 0–3) was determined using receiver operating characteristic (ROC) curve analysis, maximising both sensitivity and specificity. Factors associated with IVG were identified using multivariate logistic regression analyses. Results: Among 228 included patients, ROC analysis identified an optimal IVG threshold of 105 mL for predicting favourable 90-day outcomes (area under the curve=0.71; specificity=0.85, sensitivity=0.53). Patients were stratified into mild (IVG <105 mL, n=150) and severe (IVG ≥105 mL, n=78) groups. Multivariate logistic regression identified BIV (OR 1.02, 95% CI 1.00 to 1.03; p<0.01), admission blood glucose (OR 1.20, 95% CI 1.04 to 1.37; p=0.01), time from puncture to recanalisation (OR 1.01, 95% CI 1.00 to 1.02; p=0.049) and recanalisation at 36 hours (±12 hours) (OR 0.19, 95% CI 0.05 to 0.72; p=0.01) as independent factors associated with IVG. Conclusion: IVG after MT significantly correlates with clinical outcomes. Identification of modifiable IVG determinants after MT may inform periprocedural management strategies in patients with large infarct due to LVO. Trial registration number: NCT04551664 .
- 29 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (5) , 676-687
Significance of occlusion site on outcomes in stroke patients with large infarction undergoing endovascular therapy: A prespecified subgroup analysis of the ANGEL-ASPECT trial
Background: Randomized studies have demonstrated the efficacy of endovascular therapy (EVT) for acute large vessel occlusion with large infarction. However, the impact of the occlusion site on EVT outcomes remains underexplored. Methods: We conducted this prespecified subgroup analysis of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core (ANGEL-ASPECT) trial. Participants were enrolled within 24 h of symptom onset and had an Alberta Stroke Program Early Computed Tomography Score of 3 to 5 or an infarct core volume of 70–100 mL and were randomly assigned to undergo EVT or standard medical management (MM). All 455 patients were included and categorized into 2 subgroups by whether there was an internal carotid artery occlusion (ICAO) or middle cerebral artery occlusion (MCAO). The primary outcome was functional outcome (modified Rankin Scale) at 90 days. We further assessed the association between onset-to-puncture time (OPT) and outcome in both groups using ordinal logistic regression and tested for an interaction between occlusion site and the effect of EVT. Results: A total of 164 patients (36.0%) had ICAO, while 291 patients (64.0%) had MCAO. The baseline characteristics of patients treated with EVT and MM were comparable in either the ICAO or MCAO groups. EVT benefit was observed in both groups without significant heterogeneity (p for interaction = 0.891). A significant statistic interaction between occlusion site and treatment on any intracranial hemorrhage (ICH) within 48 h was observed (p for interaction = 0.002), with ICAO significantly increasing the risk of ICH compared to MCAO in patients undergoing EVT (ICAO: common OR, 6.34; 95% CI, 2.84–14.16; MCAO: common OR, 2.19; 95% CI, 1.56–3.09). However, the risk of symptomatic ICH was not increased significantly in both groups. For patients with ICAO, when OPT exceeds about 10 h and 10 min, the benefit of EVT compared to MM is not significant. Conclusions: Although both ICAO and MCAO patients with large infarction could benefit from EVT, EVT increased the risk of any ICH in ICAO patients without increasing the risk of sICH. Longer OPT was associated with poorer EVT efficacy in patients with ICAO. Data access statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04551664.
- 29 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (5) , 676-687
Significance of occlusion site on outcomes in stroke patients with large infarction undergoing endovascular therapy: A prespecified subgroup analysis of the ANGEL-ASPECT trial
Background: Randomized studies have demonstrated the efficacy of endovascular therapy (EVT) for acute large vessel occlusion with large infarction. However, the impact of the occlusion site on EVT outcomes remains underexplored. Methods: We conducted this prespecified subgroup analysis of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core (ANGEL-ASPECT) trial. Participants were enrolled within 24 h of symptom onset and had an Alberta Stroke Program Early Computed Tomography Score of 3 to 5 or an infarct core volume of 70–100 mL and were randomly assigned to undergo EVT or standard medical management (MM). All 455 patients were included and categorized into 2 subgroups by whether there was an internal carotid artery occlusion (ICAO) or middle cerebral artery occlusion (MCAO). The primary outcome was functional outcome (modified Rankin Scale) at 90 days. We further assessed the association between onset-to-puncture time (OPT) and outcome in both groups using ordinal logistic regression and tested for an interaction between occlusion site and the effect of EVT. Results: A total of 164 patients (36.0%) had ICAO, while 291 patients (64.0%) had MCAO. The baseline characteristics of patients treated with EVT and MM were comparable in either the ICAO or MCAO groups. EVT benefit was observed in both groups without significant heterogeneity (p for interaction = 0.891). A significant statistic interaction between occlusion site and treatment on any intracranial hemorrhage (ICH) within 48 h was observed (p for interaction = 0.002), with ICAO significantly increasing the risk of ICH compared to MCAO in patients undergoing EVT (ICAO: common OR, 6.34; 95% CI, 2.84–14.16; MCAO: common OR, 2.19; 95% CI, 1.56–3.09). However, the risk of symptomatic ICH was not increased significantly in both groups. For patients with ICAO, when OPT exceeds about 10 h and 10 min, the benefit of EVT compared to MM is not significant. Conclusions: Although both ICAO and MCAO patients with large infarction could benefit from EVT, EVT increased the risk of any ICH in ICAO patients without increasing the risk of sICH. Longer OPT was associated with poorer EVT efficacy in patients with ICAO. Data access statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04551664.
- 18 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (20) , 1397-1407
Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT
BACKGROUND: The long-term benefits of bailout intracranial angioplasty or stenting (BAOS) after thrombectomy in patients with acute large vessel occlusion remain unclear. This study compared BAOS with standard therapy in patients with large vessel occlusion with unsuccessful recanalization (expanded Thrombolysis In Cerebral Infarction score 0–2a) or >70% residual stenosis after thrombectomy. METHODS: ANGEL-REBOOT (Randomized Study of Bailout Intracranial Angioplasty Following Thrombectomy for Acute Large Vessel Occlusion) was a multicenter, open-label, blinded–end point, randomized trial conducted across 36 Chinese hospitals. Patients ≥18 years of age with anterior or posterior circulation large vessel occlusion within 24 hours of stroke onset were enrolled. After identification of thrombectomy failure or high-grade residual stenosis, patients were randomly assigned to the BAOS group (intervention) or the standard therapy group (control), in which thrombectomy was continued or terminated. The use of tirofiban was permitted in both groups during and after the procedure. In the intention-to-treat population, the primary outcome was analyzed using an assumption-free ordinal analysis (Wilcoxon-Mann-Whitney test) to compare the modified Rankin Scale scores (ordinal variable ranging from 0 to 6) between groups at 1-year follow-up, from which the generalized odds ratio was derived. Secondary outcomes included stroke recurrence in the treated artery and all-cause mortality within 1 year, analyzed using Cox proportional hazards models. RESULTS: A total of 348 patients were randomly assigned (176 to the BAOS group and 172 to the standard therapy group) and followed for 90 days, from December 19, 2021, to June 2, 2023. Of these, 326 patients (166 in the BAOS group and 160 in the standard therapy group) completed the 1-year follow-up. Compared with standard therapy, BAOS significantly improved the 1-year modified Rankin Scale score distribution (generalized odds ratio, 1.34 [95% CI, 1.05–1.73]; P =0.02). Fewer stroke recurrences in the treated artery occurred in the BAOS group than in the standard therapy group (7 of 166 [4%] versus 21 of 160 [13%]; hazard ratio, 0.30 [95% CI, 0.13–0.71]; P =0.006). One-year mortality rates were similar between groups (25 of 166 [15%] versus 27 of 160 [17%]; hazard ratio, 0.87 [95% CI, 0.50–1.50]). CONCLUSIONS: Among Chinese patients with large vessel occlusion with unsuccessful recanalization or high-grade residual stenosis after thrombectomy, BAOS was associated with reduced disability and stroke recurrence after 1 year compared with standard therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05122286.
- 18 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (20) , 1397-1407
Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT
BACKGROUND: The long-term benefits of bailout intracranial angioplasty or stenting (BAOS) after thrombectomy in patients with acute large vessel occlusion remain unclear. This study compared BAOS with standard therapy in patients with large vessel occlusion with unsuccessful recanalization (expanded Thrombolysis In Cerebral Infarction score 0–2a) or >70% residual stenosis after thrombectomy. METHODS: ANGEL-REBOOT (Randomized Study of Bailout Intracranial Angioplasty Following Thrombectomy for Acute Large Vessel Occlusion) was a multicenter, open-label, blinded–end point, randomized trial conducted across 36 Chinese hospitals. Patients ≥18 years of age with anterior or posterior circulation large vessel occlusion within 24 hours of stroke onset were enrolled. After identification of thrombectomy failure or high-grade residual stenosis, patients were randomly assigned to the BAOS group (intervention) or the standard therapy group (control), in which thrombectomy was continued or terminated. The use of tirofiban was permitted in both groups during and after the procedure. In the intention-to-treat population, the primary outcome was analyzed using an assumption-free ordinal analysis (Wilcoxon-Mann-Whitney test) to compare the modified Rankin Scale scores (ordinal variable ranging from 0 to 6) between groups at 1-year follow-up, from which the generalized odds ratio was derived. Secondary outcomes included stroke recurrence in the treated artery and all-cause mortality within 1 year, analyzed using Cox proportional hazards models. RESULTS: A total of 348 patients were randomly assigned (176 to the BAOS group and 172 to the standard therapy group) and followed for 90 days, from December 19, 2021, to June 2, 2023. Of these, 326 patients (166 in the BAOS group and 160 in the standard therapy group) completed the 1-year follow-up. Compared with standard therapy, BAOS significantly improved the 1-year modified Rankin Scale score distribution (generalized odds ratio, 1.34 [95% CI, 1.05–1.73]; P =0.02). Fewer stroke recurrences in the treated artery occurred in the BAOS group than in the standard therapy group (7 of 166 [4%] versus 21 of 160 [13%]; hazard ratio, 0.30 [95% CI, 0.13–0.71]; P =0.006). One-year mortality rates were similar between groups (25 of 166 [15%] versus 27 of 160 [17%]; hazard ratio, 0.87 [95% CI, 0.50–1.50]). CONCLUSIONS: Among Chinese patients with large vessel occlusion with unsuccessful recanalization or high-grade residual stenosis after thrombectomy, BAOS was associated with reduced disability and stroke recurrence after 1 year compared with standard therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05122286.
- Open Access
- 28 October 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (3) , 381-388
Contact aspiration versus stent retriever thrombectomy for acute basilar artery occlusion (ANGEL-COAST): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint trial
Background: Contact aspiration (CA) and stent retriever (SR) thrombectomy are two equally recommended first-line endovascular techniques for treating acute ischaemic stroke due to large vessel occlusion. Whether CA is more effective in achieving complete reperfusion compared with SR in patients with acute basilar artery occlusion (ABAO) remains unclear. Aim: This study aims to compare the efficacy and safety of CA versus SR as the first-line strategy during endovascular treatment in improving the rates of first-pass effect (FPE) for patients with ABAO. Methods and design: The ANGEL-COAST study is a prospective, multicentre, randomised controlled, open-label, blinded-endpoint (PROBE) clinical trial. Patients with acute ischaemic stroke due to ABAO within 24 hours from symptom onset will be recruited. Participants will be randomly assigned in a 1:1 ratio to either the CA or SR group. If the assigned treatment fails after three attempts, investigators may opt for alternative treatment strategies based on their clinical judgement. Study outcomes: The primary endpoint is the FPE rate, defined as eTICI (Extended Thrombolysis in Cerebral Infarction) 2C/3 recanalisation after the first thrombectomy attempt without any rescue strategy. Key secondary endpoints include rates of modified FPE (eTICI ≥2b50), successful recanalisation (eTICI ≥2b50, eTICI ≥2b67, eTICI3) within ≤3 passes with the assigned device on conclusion of the procedure, procedural duration, use of rescue techniques and functional outcomes at 90 days, including modified Rankin Scale (mRS) 0–2 and mRS ordinal shift analysis. Safety outcomes include the rates of symptomatic intracerebral haemorrhage (sICH) at 36±12 hours, all-cause 90-day mortality and procedure-related serious adverse events. Discussion: This is a head-to-head randomised trial to directly compare CA and SR in ABAO. The findings will help establish the optimal first-line endovascular treatment strategy for ABAO, potentially improving clinical outcomes in this high-risk group. Trial registration number: https://www.clinicaltrials.gov ; Unique identifier: NCT05615038 .
- 28 October 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (3) , 381-388
Open AccessContact aspiration versus stent retriever thrombectomy for acute basilar artery occlusion (ANGEL-COAST): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint trial
Background: Contact aspiration (CA) and stent retriever (SR) thrombectomy are two equally recommended first-line endovascular techniques for treating acute ischaemic stroke due to large vessel occlusion. Whether CA is more effective in achieving complete reperfusion compared with SR in patients with acute basilar artery occlusion (ABAO) remains unclear. Aim: This study aims to compare the efficacy and safety of CA versus SR as the first-line strategy during endovascular treatment in improving the rates of first-pass effect (FPE) for patients with ABAO. Methods and design: The ANGEL-COAST study is a prospective, multicentre, randomised controlled, open-label, blinded-endpoint (PROBE) clinical trial. Patients with acute ischaemic stroke due to ABAO within 24 hours from symptom onset will be recruited. Participants will be randomly assigned in a 1:1 ratio to either the CA or SR group. If the assigned treatment fails after three attempts, investigators may opt for alternative treatment strategies based on their clinical judgement. Study outcomes: The primary endpoint is the FPE rate, defined as eTICI (Extended Thrombolysis in Cerebral Infarction) 2C/3 recanalisation after the first thrombectomy attempt without any rescue strategy. Key secondary endpoints include rates of modified FPE (eTICI ≥2b50), successful recanalisation (eTICI ≥2b50, eTICI ≥2b67, eTICI3) within ≤3 passes with the assigned device on conclusion of the procedure, procedural duration, use of rescue techniques and functional outcomes at 90 days, including modified Rankin Scale (mRS) 0–2 and mRS ordinal shift analysis. Safety outcomes include the rates of symptomatic intracerebral haemorrhage (sICH) at 36±12 hours, all-cause 90-day mortality and procedure-related serious adverse events. Discussion: This is a head-to-head randomised trial to directly compare CA and SR in ABAO. The findings will help establish the optimal first-line endovascular treatment strategy for ABAO, potentially improving clinical outcomes in this high-risk group. Trial registration number: https://www.clinicaltrials.gov ; Unique identifier: NCT05615038 .